Posted by Michael Wonder on 25 Aug 2023
FDA approves Veklury (remdesivir) to treat COVID-19 in people with mild to severe hepatic impairment with no dose adjustment
24 August 2023 - This approval supports Veklury’s strong safety profile and makes Veklury the only approved COVID-19 anti-viral treatment across all stages of liver disease.
Gilead Sciences today announced that the US FDA approved a supplemental new drug application for the use of Veklury (remdesivir) with no dose adjustments to treat COVID-19 in people with mild, moderate and severe hepatic impairment.
